These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 21437339)

  • 21. Drug development in oncology assisted by noninvasive optical imaging.
    Sancey L; Dufort S; Josserand V; Keramidas M; Righini C; Rome C; Faure AC; Foillard S; Roux S; Boturyn D; Tillement O; Koenig A; Boutet J; Rizo P; Dumy P; Coll JL
    Int J Pharm; 2009 Sep; 379(2):309-16. PubMed ID: 19467306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X; Wang Z
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target.
    Plummer R
    Clin Cancer Res; 2010 Sep; 16(18):4527-31. PubMed ID: 20823148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced DNA assembly technologies in drug discovery.
    Tsvetanova B; Peng L; Liang X; Li K; Hammond L; Peterson TC; Katzen F
    Expert Opin Drug Discov; 2012 May; 7(5):371-4. PubMed ID: 22468854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiome engineering.
    Sonnenburg JL
    Nature; 2015 Feb; 518(7540):S10. PubMed ID: 25715274
    [No Abstract]   [Full Text] [Related]  

  • 26. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities for yeast metabolic engineering: Lessons from synthetic biology.
    Krivoruchko A; Siewers V; Nielsen J
    Biotechnol J; 2011 Mar; 6(3):262-76. PubMed ID: 21328545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour-targeted drug and gene delivery: principles and concepts.
    Cassidy J; Schätzlein AG
    Expert Rev Mol Med; 2004 Sep; 6(19):1-17. PubMed ID: 15387893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are the biomedical sciences ready for synthetic biology?
    DeNies MS; Liu AP; Schnell S
    Biomol Concepts; 2020 Jan; 11(1):23-31. PubMed ID: 31982863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 1. 18-22 April 2009, Denver, CO, USA.
    Gale S; McGee V; Lee W
    IDrugs; 2009 Jun; 12(6):331-4. PubMed ID: 19517308
    [No Abstract]   [Full Text] [Related]  

  • 31. Overview: the art of cancer drug screening: molecular target versus milieu-based screens.
    Sawyers CL; Sausville EA
    Curr Opin Investig Drugs; 2002 Mar; 3(3):478-81. PubMed ID: 12054100
    [No Abstract]   [Full Text] [Related]  

  • 32. Methods for open innovation on a genome-design platform associating scientific, commercial, and educational communities in synthetic biology.
    Toyoda T
    Methods Enzymol; 2011; 498():189-203. PubMed ID: 21601679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-Gen Gene Synthesis Enables Large-Scale Engineering in Biological Systems: Recent advances in synthetic biology are making this field more promising than ever.
    Leake D
    IEEE Pulse; 2015; 6(5):26-8. PubMed ID: 26414790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 36. The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow.
    Pors K; Goldberg FW; Leamon CP; Rigby AC; Snyder SA; Falconer RA
    Drug Discov Today; 2009 Nov; 14(21-22):1045-50. PubMed ID: 19638319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.
    Prestwich GD
    Acc Chem Res; 2008 Jan; 41(1):139-48. PubMed ID: 17655274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purified cell-free systems as standard parts for synthetic biology.
    Matsubayashi H; Ueda T
    Curr Opin Chem Biol; 2014 Oct; 22():158-62. PubMed ID: 25438802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic biology moving into the clinic.
    Ruder WC; Lu T; Collins JJ
    Science; 2011 Sep; 333(6047):1248-52. PubMed ID: 21885773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool.
    Kaneda Y
    Expert Opin Drug Deliv; 2010 Sep; 7(9):1079-93. PubMed ID: 20716020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.